First Tracks Biotherapeutics (HAM:B43) EBIT per Share: € (TTM As of Dec. 2024)


HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €32.00
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics EBIT per Share?

First Tracks Biotherapeutics HAM:B43 +29.29% 20 EBIT per Share is € as of Dec. 2024. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,173 Biotechnology companies, First Tracks Biotherapeutics ranks worse than 85251.41% on this metric.

First Tracks Biotherapeutics's EBIT per Share for the six months ended in Dec. 2024 was €-4.98. First Tracks Biotherapeutics does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for First Tracks Biotherapeutics's EBIT per Share or its related term are showing as below:

HAM:B43's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

First Tracks Biotherapeutics's EBIT for the six months ended in Dec. 2024 was €-172.95 Mil.

First Tracks Biotherapeutics  (HAM:B43) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

First Tracks Biotherapeutics EBIT per Share Related Terms

First Tracks Biotherapeutics EBIT per Share Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics EBIT per Share Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
EBIT per Share
-3.13 -4.98

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
EBIT per Share -3.13 -4.98
HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

First Tracks Biotherapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBIT per Share(A: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-172.951/34.749
=-4.98

First Tracks Biotherapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

EBIT per Share(Q: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-172.951/34.749
=-4.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of € mean?
First Tracks Biotherapeutics (HAM:B43) has a EBIT per Share of € as of Dec. 2024. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 1173 companies in the Biotechnology industry.
Is First Tracks Biotherapeutics' EBIT per Share too high?
First Tracks Biotherapeutics' current EBIT per Share is €. Based on the distribution chart, First Tracks Biotherapeutics ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' EBIT per Share compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 1173 companies for EBIT per Share. This places First Tracks Biotherapeutics in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on First Tracks Biotherapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. First Tracks Biotherapeutics's current EBIT per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current EBIT per Share of €. The current EBIT per Share is €. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current EBIT per Share is € as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price